Efficacy of a slow-release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): An open, multicentre longitudinal study

Clinical Endocrinology

Volumn 67, Issue 4, 2007, Pages 512-519

  Ronchi, C L ^a,k   Boschetti, M ^b   Uberti, E C Degli ^c   Mariotti, S ^d   Grottoli, S ^e   Loli, P ^f   Lombardi, G ^g   Tamburrano, G ^h   Arvigo, M ^b   Angeletti, G ⁱ   Boscani, P F ^j   Beck Peccoz, P ^a   Arosio, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b DiSEM Department of Endocrinology and Metabolism   (Italy)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF CAGLIARI   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f OSPEDALE NIGUARDA CA GRANDA   (Italy)

^g UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY OF PERUGIA   (Italy)

^j IPSEN   (France)

^k FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; AUTOGEL; GROWTH HORMONE; OCTREOTIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACROMEGALY; ADULT; AGED; ARTICLE; BILIARY TRACT DISEASE; BLIRIARY SLUDGE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; GALLSTONE; GASTROINTESTINAL SYMPTOM; GROWTH HORMONE BLOOD LEVEL; HUMAN; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SLOW RELEASE FORMULATION; TREATMENT DURATION;

ACROMEGALY; ADULT; AGED; ANALYSIS OF VARIANCE; CARRIER PROTEINS; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLYCOPROTEINS; GROWTH HORMONE; HUMANS; INJECTIONS, INTRAMUSCULAR; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; PROLACTIN; SOMATOSTATIN;

EID: 34548665710     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.02917.x     Document Type: Article

References (39)

1. Lamberts, S.W., van der Lely, A.J., de Herder, W.W. Hofland, L.J. (1996) Octreotide. New England Journal of Medicine, 334, 246 254.
2. Colao, A., Ferone, D., Marzullo, P., Cappabianca, P., Cirillo, S., Boerlin, V., Lancranjan, I. Lombardi, G. (2001) Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. Journal of Clinical Endocrinology and Metabolism, 86, 2779 2786.
3. Bevan, J.S., Atkin, S.L., Atkinson, A.B., Bouloux, P.M., Hanna, F., Harris, P.E. et al 2002) Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Journal of Clinical Endocrinology and Metabolism, 87, 4554 4563.
4. Sheppard, M.C. (2003) Primary medical therapy for acromegaly. Clinical Endocrinology, 58, 387 399.
5. Freda, P.U., Katznelson, L., van der Lely, A.J., Reyes, C.M., Zhao, S. Rabinowitz, D. (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 90, 4465 4473.
6. Cozzi, R., Montini, M., Attanasio, R., Albizzi, M., Lasio, G., Lodrini, S., Doneda, P., Cortesi, L. Pagani, G. (2006) Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. Journal of Clinical Endocrinology and Metabolism, 91, 1397 1403.
7. Giusti, M., Gussoni, G., Cuttica, C.M., Giordano, G. the Italian Multicenter Slow Release Lanreotide Study Group 1999) Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report of an Italian multicenter study. Journal of Clinical Endocrinology and Metabolism, 81, 2089 2097.
8. Baldelli, R., Colao, A., Razzore, P., Jaffrain-Rea, M.L., Marzullo, P., Ciccarelli, E., Ferretti, E., Ferone, D., Gaia, D., Camanni, F., Lombardi, G. Tamburrano, G. (2000) Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). Journal of Clinical Endocrinology and Metabolism, 85, 4099 4103.
9. Verhelst, J.A., Pedroncelli, A.M., Abstract, R., Montini, M., Vandeweghe, M.V., Albani, G., Maiter, D., Pagani, M.D., Legros, J.J., Gianola, D., Bex, M., Poppe, K., Mockel, J. Pagani, G. (2000) Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients. European Journal of Endocrinology, 143, 577 584.
10. Chanson, P., Leselbaum, A., Blumberg, J. Schaison, G. (2000) Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly: a 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on lanreotide in acromegaly. Pituitary, 2, 269 276.
11. Ambrosio, M.R., Franceschetti, P., Bondanelli, M., Doga, M., Maffei, P., Baldelli, R., Tamburrano, G., Sicolo, N., Giustina, A. degli Uberti, E.C. (2002) Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly. Metabolism, 51, 387 393.
12. Attanasio, R., Baldelli, R., Pivonello, R., Grottoli, S., Bocca, L., Gasco, V., Giusti, M., Tamburrano, G., Colao, A. Cozzi, R. (2003) Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. Journal of Clinical Endocrinology and Metabolism, 88, 5258 5265.
13. Colao, A., Ferone, D., Marzullo, P. Lombardi, G. (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocrine Reviews, 25, 102 152.
14. Antonijoan, R.M., Barbanoj, M.J., Cordero, J.A., Peraire, C., Obach, R., Valles, J., Cherif-Cheikh, R., Torres, M.L., Bismuth, F. Montes, M. (2004) Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. Journal of Pharmacy and Pharmacology, 56, 471 476.
15. Bronstein, M., Musolino, N., Jallad, R., Cendros, J.M., Ramis, J., Obach, R., Leselbaum, A. Catus, F. (2005) Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clinical Endocrinology, 63, 514 519.
16. Ciccarelli, A., Daly, A. Beckers, A. (2004) Lanreotide Autogel for acromegaly: a new addition to the treatment armamentarium. Treatments in Endocrinology, 3, 77 81.
17. Caron, P., Beckers, A., Cullen, D.R., Goth, M.I., Gutt, B., Laurberg, P., Pico, A.M., Valimaki, M. Zgliczynski, W. (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 99 104.
18. Van Thiel, S.W., Romijn, J.A., Biermasz, N.R., Ballieux, B.E., Frolich, M., Smit, J.W., Corssmit, E.P., Roelfsema, F. Pereira, A.M. (2004) Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. European Journal of Endocrinology, 150, 489 495.
19. Ashwell, S.G., Bevan, J.S., Edwards, O.M., Harris, M.M., Holmes, C., Middleton, M.A. James, R.A. (2004) The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. European Journal of Endocrinology, 150, 473 480.
20. Alexopoulou, O., Abrams, P., Verhelst, J., Poppe, K., Velkeniers, B., Abstract, R. Maiter, D. (2004) Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. European Journal of Endocrinology, 151, 317 324.
21. Gutt, B., Bidlingmaier, M., Kretschmar, K., Dieterle, C., Steffin, B. Schopohl, J. (2005) Four-year follow-up of acromegalic patients treated with the new long-acting formulation of Lanreotide (Lanreotide Autogel). Experimental and Clinical Endocrinology and Diabetes, 113, 139 144.
22. Caron, P., Cogne, M., Raingeard, I., Bex-Bachellerie, V. Kuhn, J.M. (2006) Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clinical Endocrinology, 64, 209 214.
23. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. Turner, R.C. (1985) Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, 412 419.
24. Matsuda, M. DeFronzo, R.A. (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care, 22, 1462 1470.
25. Daughaday, W.H., Kapadia, M. Mariz, I.K. (1986) Serum somatomedin binding proteins: physiologic significance and interference in radioligand assay. Journal of Laboratory and Clinical Medicine, 109, 335 363.
26. 125I]IGF-I. Journal of Clinical Endocrinology and Metabolism, 80, 1318 1324.
27. Reubi, J.C. Landolt, A.M. (1989) The growth hormone responses to octreotide in acromegaly correlate with adenoma sandostatin receptor status. Journal of Clinical Endocrinology and Metabolism, 68, 844 850.
28. Filopanti, M., Ronchi, C., Ballaré, E., Bondioni, S., Lania, A.G., Losa, M., Gelmini, S., Peri, A., Orlando, C., Beck-Peccoz, P. Spada, A. (2005) Analysis of somatostatin receptors 2 and 5 polymorphisms in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 90, 4824 4828.
29. Arosio, M., Garrone, S., Bruzzi, P., Faglia, G. Barreca, A. (2001) Diagnostic value of the acid-labile subunit in acromegaly: evaluation in comparison with insulin-like growth factor (IGF) I, and IGF-binding protein-1-2, and -3. Journal of Clinical Endocrinology and Metabolism, 86, 1091 1098.
30. Epaminonda, P., Porretti, S., Cappiello, V., Beck-Peccoz, P., Faglia, G. Arosio, M. (2001) Efficacy of radiotherapy in normalizing serum IGF-I, acid-labile subunit (ALS) and IGFBP-3 levels in acromegaly. Clinical Endocrinology, 55, 183 191.
31. Feelders, R.A., Bidlingmaier, M., Strasburger, C.J., Janssen, J.A., Uitterlinden, P., Hofland, L.J., Lamberts, S.W., van der Lely, A.J. de Herder, W.W. (2005) Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. Journal of Clinical Endocrinology and Metabolism, 90, 6480 6489.
32. Barreca, A.M., Voci, A., Lee, P.D., Arvigo, M., Ghigliotti, V., Fugassa, E., Giordano, G. Minuto, F. (1997) Effect of the somatostatin analog, octreotide, and of other hormones on the release of the acid-labile subunit of the 150 kDa complex by rat hepatocyte in primary culture. European Journal of Endocrinology, 137, 193 199.
33. Jenkins, P.J., Akker, S., Chew, S.L., Besser, G.M., Monson, J.P. Grossman, A.B. (2000) Optimal dosage interval for depot somatostatin analogue therapy in acromegaly requires individual titration. Clinical Endocrinology, 53, 719 724.
34. Turner, H.E., Thornton-Jones, V.A. Wass, J.A. (2004) Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly. Clinical Endocrinology, 61, 224 231.
35. Arosio, M., Macchelli, S., Rossi, C.M., Casati, G., Biella, O., Faglia, G. the Italian Multicenter Study Group 1995) Effects of treatment with octreotide in acromegalic patients - a multicenter Italian study. European Journal of Endocrinology, 133, 430 439.
36. Clemmons, D.R., Chihara, K., Freda, P.U., Ho, K.K., Klibanski, A., Melmed, S., Shalet, S.M., Strasburger, C.J., Trainer, P.J. Thorner, M.O. (2003) Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. Journal of Clinical Endocrinology and Metabolism, 88, 4759 4767.
37. Baldelli, R., Battista, C., Leonetti, F., Ghiggi, M.R., Ribaudo, M.C., Paoloni, A., D'Amico, E., Ferretti, E., Baratta, R., Liuzzi, A., Trischitta, V. Tamburrano, G. (2003) Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. Clinical Endocrinology, 59, 492 499.
38. Ronchi, C.L., Orsi, E., Giavoli, C., Cappiello, V., Epaminonda, P., Beck-Peccoz, P. Arosio, M. (2003) Evaluation of insulin resistance in acromegalic patients before and after treatment with somatostatin analogues. Journal of Endocrinological Investigation, 26, 533 538.
39. Ronchi, C.L., Varca, V., Beck-Peccoz, P., Orsi, E., Donadio, F., Baccarelli, A., Giavoli, C., Ferrante, E., Lania, A., Spada, A. Arosio, M. (2006) Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors. Journal of Clinical Endocrinology and Metabolism, 91, 121 128.